Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Evkeeza is a prescription monoclonal antibody containing evinacumab-dgnb. It is an angiopoietin-like 3 inhibitor used with diet, exercise, and other LDL cholesterol-lowering therapies to reduce LDL cholesterol in adults and children age 1 and older with homozygous familial hypercholesterolemia.
read more about evkeeza ...Evinacumab-dgnb binds to and inhibits ANGPTL3, a liver-derived protein involved in lipid metabolism. ANGPTL3 normally inhibits lipoprotein lipase and endothelial lipase. Blocking ANGPTL3 lowers LDL cholesterol, triglycerides, and high-density lipoprotein cholesterol.
Evkeeza is indicated for adults and pediatric patients age 1 and older with homozygous familial hypercholesterolemia. It is used alongside diet, exercise, and other LDL cholesterol-lowering therapies. The labeled dose is the same weight-based regimen across eligible age groups.
The recommended dose is 15 mg per kg by intravenous infusion once every four weeks. The diluted medicine is infused over 60 minutes through an intravenous line with the specified filter. LDL cholesterol can be assessed after treatment begins to measure response.
Serious hypersensitivity reactions, including anaphylaxis, have occurred with Evkeeza. Treatment is contraindicated in patients with a history of serious hypersensitivity to evinacumab-dgnb or its ingredients. Animal data indicate fetal harm risk, and patients who can become pregnant use contraception during treatment and for five months after the final dose.
Evkeeza lowers LDL cholesterol in adults and children age 1 and older with homozygous familial hypercholesterolemia.
Evkeeza is infused intravenously at 15 mg per kg once every four weeks.
The diluted dose is administered by intravenous infusion over 60 minutes.
Yes. Serious hypersensitivity reactions, including anaphylaxis, have occurred during treatment.
DailyMed - EVKEEZA (evinacumab-dgnb) injection, solution, concentrate. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=73412138-6d8f-4ea6-bb72-a740190470ff. Date Accessed September 30, 2026.
Evinacumab. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK572294/. Date Accessed September 30, 2026.
Evinacumab. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Evinacumab. Date Accessed September 30, 2026.
Evinacumab. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK597342/. Date Accessed September 30, 2026.
Evinacumab-dgnb Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621023.html. Date Accessed September 30, 2026.